INT85608

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 1.76
Pain Relevance 1.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SLC6A1) plasma membrane (SLC6A1) transmembrane transport (SLC6A1)
Anatomy Link Frequency
neuronal 1
SLC6A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
gABA 91 100.00 Very High Very High Very High
Hippocampus 1 99.20 Very High Very High Very High
Analgesic 3 98.00 Very High Very High Very High
Bioavailability 1 97.72 Very High Very High Very High
agonist 8 97.20 Very High Very High Very High
central pain 20 93.44 High High
Central nervous system 17 91.36 High High
GABA receptor 2 86.32 High High
headache 1 62.56 Quite High
Pain 11 62.48 Quite High
Disease Link Frequency Relevance Heat
Scotoma 1 98.76 Very High Very High Very High
Anxiety Disorder 6 95.28 Very High Very High Very High
Pain 30 92.80 High High
Epilepsy 2 87.52 High High
Disease 4 84.56 Quite High
Convulsion 2 81.84 Quite High
Toxicity 2 80.88 Quite High
Partial Seizures 1 71.92 Quite High
Dizziness 1 63.44 Quite High
Headache 1 62.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Gabitril (tiagabine) is a potent selective inhibitor of the principal neuronal gamma-aminobutyric acid (GABA) transporter (GAT-1) in the cortex and hippocampus.
Negative_regulation (inhibitor) of GAT-1 in neuronal associated with gaba and hippocampus
1) Confidence 0.53 Published 1999 Journal Epilepsia Section Abstract Doc Link 10612355 Disease Relevance 0.32 Pain Relevance 0.21
Tiagabine is currently the only selective GABA reuptake inhibitor available in US markets; it exerts its action via GAT-1 transporter blockade presynaptically, facilitating GABA neurotransmission.
Negative_regulation (blockade) of GAT-1 associated with gaba
2) Confidence 0.33 Published 2006 Journal Expert Opin Pharmacother Section Abstract Doc Link 17020423 Disease Relevance 0.66 Pain Relevance 0.21
For example, vigabatrin, a GABA agonist with good bioavailability and analgesic action, produced visual field defects in 1/3 of patients during therapy and tiagabine, a selective inhibitor of GABA transport (GAT1), took twenty years to bring to market.17,18
Negative_regulation (inhibitor) of GAT1 associated with scotoma, gaba, analgesic, agonist and bioavailability
3) Confidence 0.07 Published 2010 Journal Perspect Medicin Chem Section Body Doc Link PMC2918363 Disease Relevance 0.78 Pain Relevance 1.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox